AAAAI 2021 Results of the SYNAPSE study for CRSwNP
Medscape ReCAP of new science at the American Rhinologic Society 2020 virtual meeting
Targeting Inflammation: Biologic Immunomodulators For Moderate-to-Severe Chronic Rhinosinusitis with Nasal Polyps – An Animated Whiteboard View
This enduring activity is focused on the care of patients with chronic rhinosinusitis with nasal polyps.
Stella E. Lee, MD
Chronic Rhinosinusitis with Nasal Polyps — Dupilumab, a New Therapy
Chronic Rhinosinusitis With Nasal Polyposis: Early Diagnosis
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common condition that significantly affects quality of life and results in more than a million surgeries a year worldwide.
Symptoms of CRSwNP often mimic allergic rhinitis or bacterial rhinosinusitis, and patients frequently receive inappropriate prescriptions for allergy medications and even multiple courses of antibiotics. But appropriate therapeutic intervention can help to relieve CRSwNP symptoms, prevent unnecessary pain and suffering, reduce disease progression, and potentially prevent the need for nasal polypectomy.
Dr Stella Lee from the University of Pittsburgh discusses the importance of early and accurate diagnosis of CRSwNP, which is now viewed as a long-term, systemic inflammatory disorder, as well as strategies to assess symptom and disease severity.
References
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size
EUFOREA consensus on biologics for CRSwNP with or without asthma
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials